Drugs / INV-102
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05586152 | Aug 2022 → May 2023 | dry eye syndrome | Invirsa, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06599684 | Sep 2024 → Sep 2025 | diabetic macular edema | Invirsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06370039 | Mar → Jul 2024 | dry eye syndrome | Invirsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05636228 | Jun 2023 → Aug 2024 | keratoconjunctivitis | Invirsa, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06370039 ↗ |
| Route | Topical | “topically administered eyedrops” NCT05586152 ↗ |